Supporters Company Profile


Alpha Tau Medical Ltd.
School of Physics, Tel Aviv University
P.O. Box 39040
Tel Aviv 6997801, Israel


Alpha Tau Medical focuses on research, development and commercialization of Alpha DaRT (Diffusing Alpha-Emitters Radiation Therapy) for the treatment of solid tumors.
Alpha DaRT, initially developed at Tel Aviv University, was shown to be effective and safe for treating different types of cancer in multiple preclinical and clinical studies.
Alpha DaRT has several important advantages:
• Highly potent and conformal
• Proven efficacy for all solid tumors tested
• Effective regardless of tumor oxygen level
• Short half-life – quick clinical outcome
• No known negative systemic effects
• Single-session treatment
• Enables combination therapy or reapplication
• Disposable applicators - does not require capital equipment or special shielding




American Well uses telehealth to improve people’s access to quality care. Through our partnerships with the nation’s largest health systems, insurers, employers, and retailers, our award-winning telehealth Exchange and our direct-to-consumer service, Amwell™, we connect millions of Americans to the doctors they trust for live video visits. Through the power of telehealth, we help patients get the care they need in a timely fashion, and help doctors be there for their patients. We build technologies to make healthcare go where people need it most. For more on how we are changing healthcare delivery through telehealth, visit

American Well and Amwell are registered trademarks or trademarks of American Well Corporation in the United States and other countries. All other trademarks used herein are the property of their respective owners.



AMI Technologies ltd - is a leading distributor of medical devices and innovative technology in Israel. The company was established in 1986 and is a leading Medical industry for over 30 years and gained vast experience and knowledge.



Since 1958 Amos Gazit Ltd. Is a leading company, privately owned, in the Medical and Industrial Safety fields in Israel. Amos Gazit Ltd, in conjunction with leading manufacturers world-wide (Including Boston Scientific, Drager, Smiths Medical, Zimmer Biomet etc.), constantly updates and introduces to the Israeli market the latest improvements and technologies, while maintaining the highest level of quality and integrity.

  Astellas Pharma EMEA operates in 40 countries across Europe, the Middle East and Africa, and is the EMEA regional business of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. The organisation's focus is to deliver outstanding R&D and marketing to continue growing in the world pharmaceutical market. Astellas presence in Europe also includes an R&D site and three manufacturing plants. The company employs over 4,500 people across the EMEA region. In 2013 Astellas was awarded SCRIP Pharmaceutical Company of the Year in recognition of its commercial success and pipeline development.


Benesch is an AmLaw 200 business law firm with offices in Chicago, Cleveland, Columbus, Hackensack, Indianapolis, Shanghai and Wilmington. The firm is known for providing highly sophisticated legal services to national and international clients that include public and private, middle market and emerging companies as well as private equity funds, entrepreneurs, not-for-profit organizations, trusts and estates. Benesch’s core practice areas include Corporate & Securities, Health Care, Innovations, Information Technology & Intellectual Property, Labor & Employment, Litigation, and Real Estate & Environmental. Some of the industries the firm concentrates in include Private Equity, Agribusiness, Packaging, Specialty Chemicals, Coatings and Adhesives, Specialty Distribution, Banking, Health Care, Polymers, Transportation & Logistics, Energy & Natural Resources, Shale Oil & Gas, Construction and Not-for-Profit.


Breslauer LTD
58B Amal Street
POB 10082
Petach Tikvah
ISRAEL 4900102
Tel.: +972-3-9187000
Fax: +972-3-9222646


Established in 1939, Breslauer LTD is a leading value added distributor that provides a wide range of solutions for hospitals and clinics. In the urology field, Breslauer LTD exclusively represents several of the renowned global companies, including the following:
KARL STORS - Endo-Urology, Laparoscopic Surgeries, OR1.
STORZ MEDICAL - Shockwave Lithotripsy, Shockwave Therapy.
STERIS - Sterile Reprocessing Equipment, OR Table and Light.
MMS - Urodynamics and Anorectal Manometry.
ROCAMED – Endo- Urology Fluid Management (ENDOFLOW), Disposables for Endo-Urology.
MEDIFA – Urology Examination Chairs.


Butterfly Medical is developing a minimally invasive treatment for enlarged prostate (BPH). The Butterfly device is a metallic implant that is delivered in a matter of minutes under local anesthesia and retracts the lateral lobes of the prostatic urethra to restore urine flow.
Butterfly Medical has a CE Marked product and initial clinical data.
The Butterfly device is the only BPH treatment that can be done with a flexible cystoscope and the least invasive treatment (no damage to tissue).
The Butterfly device is designed as a permanent treatment but can be extracted at any time if needed.



Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare. Our business includes ostomy care, urology and continence care, and wound and skin care. We operate globally, employing more than 10,000 people. Closeness to all customers makes this possible. We listen to better understand needs, and respond by finding new ways to do things better together. We lead the way by bringing the best ideas first and fast to market in the form of medical devices and service solutions.



Created, owned and operated by its members, the non-profit Canadian Urology Research Consortium (CURC) is a clinical research investigator network. The Consortium is a national alliance of leading academic and community based urologists committed to furthering urology research in Canada. CURC pursues clinical trials in concert with the pharmaceutical industry to tackle urological disorders including, but not restricted to:
• prostatic diseases: hypertrophy, prostate cancer, and prostatitis
• voiding dysfunction
• erectile dysfunction
• bladder, kidney and testicular cancer
• urolithiasis
• urinary tract infections.
Together with industry CURC offers enhanced research options, which ultimately deliver better quality of life to Canadians.




Direx Group, established over 30 years ago, has continuously extended its presence in countries and markets worldwide. The Group utilizes unique breakthrough technologies for products characterized by reliability, modularity and transportability - combined with cost effectiveness and ease of use. Linear shockwave, for ED treatment, is the only technology focusing energy on a line-segment covering the entire penile length in a single application. Product lines include Shock Wave Lithotripsy (including dual-head and portable stationary patient systems), Thermal Therapy, Radiotherapy and Laser. More than a thousand systems, predominantly in Urology, have been placed in over 70 countries. Worldwide network of committed service centers assure adequate support and maintenance.


Dover Medical & Scientific Equipment Ltd.
11 Hamaalot St., Herzliya 46583
Tel.: 972-(0)9-9514545
Fax: 972-(0)9-9580151

Dover Medical & Scientific Equipment, Ltd., founded in 1974, is one of the leading companies in the Israeli medical market, incorporating revolutionary and high technologies.
Our clients include: Ministry of Health Hospitals, University Hospitals, Private Hospitals, Clinics and Research Institutes.
Dover focuses on medical and diagnostic solutions.
Our medical division covers such fields as Surgery, ICU, Urology, Gynecology, ENT, IT and hospital logistics. The procedures for some of these fields can be performed also by our da Vinci robot.
Our diagnostic division covers Lab Automation, Blood Banking, Hematology, Clinical Chemistry, Endo, Pathology, HLA and Molecular Biology.



Elmedical Bladder Wall Thermo-chemotherapy (BWT) treats nonmuscle invasive bladder cancer (NMIBC) by the powerful heat-chemotherapy synergistic combination. BWT uses fast circulation of precisely heated mitomycin (MMC) solution which provides uniform high temperature over the entire bladder lumen and yet, stability and potency of the drug is maintained due to the BWT proprietary heat-exchanger.
BWT heat-chemotherapy synergy is very effective with excellent patients’ tolerance and clinical outcomes. Clinical results of BWT in a highly recurrent (median recurrence free interval of 5 months) group of high- and intermediate-risk NMIBC patients who all failed BCG and some also failed MMC stand-alone instillations already showed, with 8 years median follow-up, about 7X extended recurrence-free interval following BWT compared to each patient baseline.
Today, more than 10,000 BWT procedures have been performed successfully with very good results.
Elmedical systems are installed in Israel, Germany, Turkey, Spain, Italy, Czech Republic, Croatia, Colombia, Switzerland and Austria (and soon in Brazil).
Elmedical already performed successfully proof of concept procedures in overactive bladder (OAB), interstitial cystitis/bladder pain syndrome (IC/BPS) and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) and will start formal clinical trials in these diseases.



  About Ferring Pharmaceuticals
Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

Getter Group Ltd
Bio-Med Division
7, Shimshom Road
Petach-Tikva 4912502

  Getter is active in a few fields with Urology products
COOK Medical Urology leading company, produce high quality products, leading the Israeli market. Urethral Stents, Dilation access and balloons, Stone extractors, Wire Guides and Catheters.
AMS has been a leading innovator in the field of erectile restoration for over three decades. Today we offer the broadest line of penile implant options in the industry.
Also is the leading innovator in developing minimally invasive treatment options for enlarged prostate or BPH (benign prostatic hyperplasia). We help physicians cover the complete spectrum of solutions for patients suffering from enlarged prostate, from mildly symptomatic to severely obstructed.
Male Sling
New outpatient technology for men suffering from mild stress urinary incontinence
Urinary Prosthesis is an implanted device designed to allow patients who have incontinence (loss of urinary control) due to prostate surgery to control urination

  Inframed is a leading distributor of innovative medical technologies and medical devices in Israel.
We implement an intensive search and development process in order to identify breakthrough medical devices that address unmet clinical needs.
Our company is committed to marketing successfully in its territory innovative, cost-effective products in high growth market segments, to investing the resources required to develop new product concepts and to ensuring a leadership position in the emerging medical technology segment.

InTouch Health
7402 Hollister Avenue | Santa Barbara, CA 93117, USA

  InTouch Health, ranked the #1 virtual care platform by KLAS, makes virtual care easy by giving health systems one scalable platform to deliver care for any use case, including direct-to-consumer telehealth. By leveraging the InTouch Operating System, configurable software modules, and a range of devices and managed services, health systems have everything they need to power a modern telehealth program.

  KOELIS, The Prostate Care Company, has assisted urologists and radiologists from around the world in their routine clinical practice since 2006, providing the latest technology for personalized prostate cancer planning and management, from biopsy to active surveillance and treatment.
Focused on developing advanced, targeted and less invasive solutions, KOELIS is committed to creating and bringing to the market a new paradigm in prostate cancer care, where physicians can offer the most personalized answers to their patients, avoiding any under or overtreatment and preserving quality of life. Thanks to cutting-edge imaging tools like Trinity® cartographer, which combines multiple imaging modalities with full 3D ultrasound, any suspicious lesion is characterized in a detailed 3D prostate map, offering a comprehensive and multiparametric approach and enhancing diagnostic confidence.

Lumenis Ltd.


Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets.
In surgery, Lumenis leads the way, offering innovative laser treatment methods, with our high-powered Holmium and CO2 laser technologies.We pioneered a clinically superior prostate surgery procedure, and innovated advanced laser lithotripsy solutions, and next-generation ENT treatments.
Eldan Instruments Ltd. is Lumenis dedicated partner with in-depth technical expertise and extensive local market knowledge in Israel.


Medison is Israel’s leading international pharmaceutical group for innovative niche healthcare solutions.
With three generations of experience Medison specializes in Oncology, Hematology and Rare Genetic Disease representing companies such as Shire, Ipsen, Amgen, GenomeDX and more.
With products like Decipher, a genomic test that informs decisions about the course of treatment for men after prostate surgery and XGEVA for the prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumors.



Sam-On (Meditec) is a family owned pharmaceutical manufacturer engaged and specialized in development, production, distribution and marketing of pharmaceuticals (Rx and OTC), special nutritional supplements and medical devices.
Sam-On (Meditec) is a fully integrated company possessing active R&D manufacturing, registration and regulatory affairs, marketing, sales and nationwide distribution capabilities, in house.
Our products are market leaders in their therapeutic categories and have driven growth of the company every year.
Sam-On (Meditec) specializes in developing and manufacturing OTC drugs containing unique formulations/combinations with an added medical value (including natural or herbal ingredients).
Sam-On (Meditec)'s portfolio includes broad therapeutic categories such as cardiovascular, gastroenterology, urology, gynecology and women's health, respiratory, diabetes and CNS disorders.




Micromedic focuses on the development and commercialization of innovative in vitro diagnostic solutions for early cancer detection. Particularly, CellDetect® is a new-generation cytopathological staining platform for the improved diagnosis of early stage bladder cancer tumors. As opposed to standard histochemical stains which only rely on morphology, CellDetect® uses both color and morphology in order to differentiate between normal and malignant cells in urine specimens. This color feature dramatically enhances the diagnostic accuracy across all cancer stages, affording high sensitivity for low grade tumors. Using equipment and processes available in all pathology laboratories, CellDetect® is also applicable to other types of cancers.



miR Scientific is a precision molecular bioscience company with a next-generation statistical science platform that creates and delivers scalable breakthrough technologies for the provision of accessible diagnostic, prognostic, monitoring and companion products and services. Its mission for at-risk cancer populations is to eliminate missed diagnoses and unnecessary or premature interventions that can result in a quality-of-life deterioration and can impose exorbitant financial burdens. Founded in 2014 as a commercial spin-out from the State of New York University at Albany’s Cancer Research Center, miR empowers patients and care providers by enabling highly accurate data-centric information to select optimal treatment and monitoring options for the patient. miR engages stakeholders across the disease continuum to adopt patient-focused innovations with measurable and meaningful outcomes. Among other planned products and services, miR has created the Prostate Cancer Sentinel Assay Test™, which has the potential to save thousands of men from suffering the potentially severe side effects of unnecessary prostate cancer treatments. miR will continue to work with key stakeholders on global clinical trials and pursue concurrent regulatory and Laboratory Developed Lab test strategies. miR welcomes international collaborations to advance novel state-of-the-art technologies that will address large cancer populations.



At Novartis Oncology, our mission is to help improve the lives of cancer patients. We are passionate about the discovery and development of innovative medicines that transform the way people live with cancer and rare diseases. We seek to provide a wide range of innovative therapies to help meet unmet medical needs, as well as practical solutions to advance the care of patients.
Novartis Oncology offers an unmatched portfolio of oncology, hematology and rare disease medicines to treat more than 25 conditions worldwide. New therapies acquired from the GSK oncology portfolio in melanoma, renal cell carcinoma and hematology complement Novartis Oncology’s existing group of practice-changing medicines to create one of the largest portfolios of drugs in oncology and hematology targeting important biological disease pathways.



Nucleix is an Israeli company which develops, manufactures and markets highly innovative and non-invasive molecular cancer diagnostic tests. Our tests are based on identification of subtle changes in methylation patterns in liquid biopsy samples (such as urine and blood). Our first product, Bladder EpiCheck®, is a CE marked urine test for monitoring of bladder cancer. Bladder EpiCheck was validated in several independent clinical studies, among them a multi-center European prospective, blinded study in leading European urology centers and shown to have 99.3% NPV, 91.7% Sensitivity for high grade tumors and 88% specificity.



At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals.
Our diversified global health care portfolio includes biologic and small molecule medicines and vaccines, as well as many of the world’s best-known consumer products.
Consistent with our responsibility as the world’s leading Biopharmaceutical Company, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.



Profound Medical is commercializing a novel technology, TULSA-PRO®, which combines real-time MRI with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control that is designed to provide precise ablation of the prostate while simultaneously protecting critical surrounding anatomy from potential side effects.
TULSA-PRO® is a promising modality for localized prostate cancer and BPH, as it enables incision-free and targeted ablation of prostate tissue. The millimetre precision, the ability to personalize the treatment to the patient’s anatomy & pathology, and the promise of providing a safe minimally invasive solution with the potential to reduce side-effects, are key advantages of this technology.



Progenetics is an innovative company in the field of onco-diagnostics and personalized medicine. Progenetics belongs to BATM, an international, stock traded company, involved in the diagnostics and medical device arena in several European countries.
The company develops, preforms and represents several cutting edge diagnostic tools in the field of Oncoloy, Gynecology and Urology.
In Urology, our leading product is the 4K-Score test - an accurate blood test for detection of aggressive prostate cancer. 4K-score is validated by 16 peer-review papers encompassing over 37,000 patients and is recommended in both NCCN and EAU guidelines.



Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).


STEBA Pharmaceutical
18 Einstein Street, Kiryat Weizmann Science Park, Ness Tziona, 7610302, Israel
Tel.: +972 8 9402900

Steba Pharmaceutical is a subsidiary of Steba Biotech, a privately-owned, biotechnology company headquartered in Luxembourg with offices in France, Israel, Switzerland and the United States. Steba Biotech, in collaboration with the Weizmann Institute of Science, has developed TOOKAD Soluble (Padeliporfin di-Potassium), a minimally invasive photodynamic therapy for treatment of low-risk prostate cancer.
TOOKAD Soluble is approved in Europe, Israel and Mexico.
For the past 5 years, Steba Biotech has also been working with TOOKAD Soluble on important research and clinical studies in immuno-oncology in collaboration with Memorial Sloan-Kettering Cancer Center (NY, USA) ,the Weizmann Institute (ISRAEL), and Oxford University (UK).



Medical Enterprises Group
Medical Enterprises Group develops innovative minimally invasive technologies. Our group consists of professional staff and leaders in the field of physics, engineering and clinical experts
The lead product, Synergo® RITE (Radiofrequency-Induced ThermoChemotherapeutic Effect) offers clinically effective, safe and easy way to deliver the tri-modality local, non-ionizing Radiofrequency radiation, chemotherapy and deep tissue hyperthermia targeted at the tissue by microwave (RF) energy.

Tec-O-Pharm-Libra Ltd.
P.O. Box 45054, Jerusalem 91450 Israel
Tel: 972-2-5870875
Fax: 972-2-5870873

Tec-O-Pharm Group is a private enterprise, founded in 1992 and based in Jerusalem. We are dedicated to providing our international partners the full range of professional services in the fields of Urology, Pain management, Anesthesia, Oncology and Women`s health.
Our leading brands Spasmex 30 and Spasmex 15 (Trospium), are the safest treatment for urinary incontinence, being the only anticholinergic molecule that is not metabolized via CYP-450 in the liver, thus avoiding drug-drug interactions, and with low probability of passing the blood brain barrier, avoiding cognitive disorders associated with other anticholinergics. Spasmex is presented in tablets of 30 mg and 15 mg, allowing maximum flexibility for the needs of the patient.



Oncotest-Teva is a pioneer in the field of personalized medicine in Israel.
For almost two decades, Oncotest-Teva has been focusing on identification of novel approaches to diagnosing malignant diseases and predicting the course of disease, according to the unique genetic profile of the patient and tumor cells, and more precise and more effective matching of therapeutic directions.
Generics Business – Teva Israel
Teva is the leading player in the Israeli generic market, selling over 300 products in all therapeutic areas.
Teva launches new products on a yearly basis that saves the Israeli government hundreds of millions of NIS.
Back integration of R&D, API and full production.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies.



UroGen Pharma Ltd. is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. The Company has developed RTGel™, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen is headquartered in Ra’anana, Israel with U.S. headquarters in New York.



Within the last 50 years, UROMED has developed into one of the leading providers of urological medical devices and drainage aids for incontinence care.
UROMED offers a comprehensive range of products for diagnosis and therapy of urological diseases. Based on long-term experience and know-how, UROMED offers its customers individual solutions to meet the requirements of users and consumers. Therefore we develop appropriate solutions using proven as well innovative technologies that are sustainable and economically viable